Cambridge Cognition’s CEO discusses expansion into new areas of brain disease study

Cambridge Cognition Holdings PLC’s Matthew Stork discusses progress on its new voice-based brain disease diagnostic and its pioneering work in the field of AI-based PTSD assessments.

A number of drugs are in development for PTSD, he says but only a couple are licensed currently, so this is potentially a major new area for the group.

It will add to new opportunities opening up in schizophrenia and neuro-oncology, he adds.

You might like

© 2022 The Latest StockMarket News and Interviews